Ginkgo Bioworks Holdings, Inc.

NYSE•DNA

CEO: Dr. Jason Kelly Ph.D.

板块: Healthcare

行业: Biotechnology

上市日期: 2021-04-19

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

联系方式

27 Drydock Avenue, 8th Floor, Boston, MA, 02210, United States

877-422-5362

www.ginkgobioworks.com

市值

$421.09M

市盈率 (TTM)

-1.2

1.3

股息率

52周最高

$17.58

52周最低

$5.00

52周范围

14%

排名66Top 96.8%

1.5

F-Score

改良版 Piotroski 分析

基于 6 年期基本面

疲弱 • 1.5 / 9 分

评分区间 (0-9)

8-9: 价值优异

6-7: 基本面强劲

4-5: 整体稳健

0-3: 表现疲弱

数据范围: 2020-2025

财务仪表盘

Q4 2025 数据

营业收入

$33.40M+0.00%

近4季度走势

每股收益

-$1.43+0.00%

近4季度走势

自由现金流

-$63.00M+0.00%

近4季度走势

2025 Annual 财报亮点

核心亮点

Operating Expenses Decline Total operating expenses fell $301.3M to $485.4M in 2025; R&D expenses decreased $180.3M reflecting restructuring.

Net Loss Narrows Net loss improved $234.3M to $(312.8)M in 2025, driven by lower operating costs and no goodwill impairment recorded.

Operating Cash Burn Reduced Net cash used in operating activities decreased $148.5M to $(171.1)M in 2025, reflecting successful cost control measures.

Biosecurity Segment Sale Agreed Entered agreement February 2026 to sell Biosecurity Business for approximately 20% equity stake in Tower Biosecurity.

关注风险

Continued Net Losses Expected Company has history of net losses; expects continued losses for foreseeable future, may never achieve profitability or sustain growth.

Critical Supplier Dependency Risks Reliance on limited, single-source suppliers for critical lab supplies exposes business to supply chain delays and cost risks.

Revenue Concentration Risk Significant revenue concentration exists; one Cell Engineering customer accounted for 15% of total 2025 revenue.

Synthetic Biology Technology Risk Rapidly changing synthetic biology technology risks making current platform, programs, and services obsolete or non-competitive.

前瞻展望

Investing in Tools Offerings Anticipates expenditures exceeding revenue; plans to further invest in and expand proprietary tools offerings and platform capabilities.

Expanding AI/ML Capabilities Continue developing and deploying generative AI and machine learning tools to enhance biological R&D efficiency and throughput.

Need for Future Capital Expects continued net losses, requiring substantial additional capital to fund business development and platform expansion.

Maintain Multi-Class Structure Expects to maintain concentrated voting power via multi-class stock structure to prioritize long-term goals over short-term results.

同行对比

营业收入 (TTM)

IOVA

$263.50M

+60.6%

ARVN

$262.60M

-0.3%

VALN

$198.55M

+13.5%

毛利率 (最新季度)

VIR

672.1%

-54902.1pp

IOVA

215.9%

+65.9pp

DNA

124.4%

-21.7pp

关键指标

股票代码	市值	市盈率 (TTM)	净资产收益率 (TTM)	负债率
IOVA	$1.31B	-4.1	-54.5%	5.3%
NRIX	$1.30B	-5.4	-57.5%	8.1%
VIR	$1.29B	-2.9	-49.3%	18.6%

长期趋势

近4季度

营业收入

净利润

经营现金流

4季度营收复合增长率

-11.6%

增长承压

4季度净利润复合增长率

N/M

盈利状态转变

现金流稳定性

现金流需要关注

深度研究

下次财报:2026年5月5日

每股收益:-

营业收入:$41.50M

财务数据

电话会议

财务报告

新闻

利润表

资产负债表

现金流量表

财务比率

变化率

利润表	过去12个月

无数据